Cytek Biosciences Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cytek Biosciences, Inc. (CTKB) Reports In-Line Q3 EPS; Offers FY22 Revenue Guidance
November 9, 2022 4:34 PM ESTCytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $40.5 million versus the consensus estimate of $43.13 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2022 revenue of $160-168 million, versus the... More
